Navigation Links
ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
Date:2/9/2009

FREDERICK, Md., Feb. 9 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of their small molecule inhibitor of HIV-1 at the 16th CROI meeting held this week in Montreal. The presentation highlighted the advanced development of ImQuest's lead HIV pyrimidinedione inhibitor, IQP-0410. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription. The data presented demonstrate that IQP-0410 is well tolerated and safe with plasma drug concentrations 10-20-fold greater than those required for complete suppression of HIV replication at 24-hours following oral administration. Thus, IQP-0410 can be dosed once per day, and possesses a highly positive safety profile which suggests it will be amenable for use in women of child bearing years. Nick Kaludov, Ph.D., Director of Scientific Operations presented the new findings which also included metabolism, safety pharmacology, and genotoxicology evaluations. The studies included ImQuest co-authors Karen Watson, M.S. and Robert W. Buckheit, Jr., Ph.D.

"The data presented today indicate that IQP-0410 may represent a next generation HIV drug with a highly unique mechanism of action and an excellent safety profile," said Dr. Buckheit, Executive Vice President and Chief Scientific Officer. "We look forward to our upcoming clinical trial and believe that IQP-0410 will be an attractive new addition to existing antiretroviral therapies for HIV infection."

ImQuest recently submitted an Investigational New Drug application to the FDA to initiate human clinical trials with IQP-0410 and is concurrently developing a new generation pyrimidinedione with an enhanced barrier to resistance from among the series of pyrimidinediones.

ImQuest Life Sciences (www.ImquestLS.com), a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences (www.Imquest.com), also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
2. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
3. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
Breaking Biology Technology:
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):